Polysorbate-Based Drug Formulations for Brain-Targeted Drug Delivery and Anticancer Therapy
Source abstract
Abstract
Polysorbates (PSs) are synthetic nonionic surfactants consisting of polyethoxy sorbitan fatty acid esters. PSs have been widely employed as emulsifiers and stabilizers in various drug formulations and food additives. Recently, various PS-based formulations have been developed for safe and efficient drug delivery. This review introduces the general features of PSs and PS-based drug carriers, summarizes recent progress in the development of PS-based drug formulations, and discusses the physicochemical properties, biological safety, P-glycoprotein inhibitory properties, and therapeutic applications of PS-based drug formulations. Additionally, recent advances in brain-targeted drug delivery using PS-based drug formulations have been highlighted. This review will help researchers understand the potential of PSs as effective drug formulation agents.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Hydrogels: synthesis, properties, applications · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Bioengineering, Incheon National University, Incheon 22012, Korea
Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul 07804, Korea
Department of Internal Medicine, Ewha Womans University Medical Center, Seoul 07804, Korea
Funding
Incheon National University
References (100+)
Show source-provided references
1. Drug delivery systems: Entering the mainstream10.1126/science.1095833 ↗
2. Trucillo, P. (2021). Drug carriers: Classification, administration, release profiles, and industrial approach. Processes, 9.10.3390/pr9030470 ↗
3. Developments of Polysorbate (Tween) based microemulsions: Preclinical drug delivery, toxicity and antimicrobial applications10.1016/j.ijpharm.2017.06.059 ↗
4. Milton, J.R., and Joy, T.K. (2012). Surfactants and interfacial phenomena. Surfactants in Biology, John Wiley & Sons.
5. Non-ionic surfactant based vesicles (niosomes) in drug delivery10.1016/S0378-5173(98)00169-0 ↗
6. Preparation and drug release study of novel nanopharmaceuticals with polysorbate 80 surface adsorption10.1155/2018/4718045 ↗
7. Performance of the biocompatible surfactant tween 80, for the formation of microemulsions suitable for new pharmaceutical processing10.1155/2013/930356 ↗
8. Szymczyk, K., Zdziennicka, A., and Jańczuk, B. (2018). Effect of polysorbates on solids wettability and their adsorption properties. Colloids Interfaces, 2.10.3390/colloids2030026 ↗
9. Food emulsifier polysorbate 80 increases intestinal absorption of di-(2-ethylhexyl) phthalate in rats10.1093/toxsci/kfu055 ↗
10. Quantitation of hydroperoxides in the aqueous solutions of non-ionic surfactants using polysorbate 80 as the model surfactant10.1016/0731-7085(93)80129-O ↗
11. Porter, M.R. (1994). Handbook of Surfactants, Chapman and Hall.10.1007/978-94-011-1332-8 ↗
12. Water-soluble nanocrystals through dual-interaction ligands10.1002/anie.200800434 ↗
13. Effective delivery of p65 shRNA by optimized Tween 85-polyethyleneimine conjugate for inhibition of tumor growth and lymphatic metastasis10.1016/j.actbio.2014.02.009 ↗
14. Self-labeled magneto nanoprobes using tri-aminated polysorbate 80 for detection of human mesenchymal stem cells10.1039/b912149h ↗
15. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles10.1023/A:1022604120952 ↗
16. Introducing Tween-curcumin niosomes: Preparation, characterization and microenvironment study10.1039/C9SM02416F ↗
17. Physical characterization and antioxidant activity of thymol solubilized Tween 80 micelles10.1038/srep38160 ↗
18. Hekmat, A., Attar, H., Seyf Kordi, A.A., Iman, M., and Jaafari, M.R. (2016). New oral formulation and in vitro evaluation of docetaxel-loaded nanomicelles. Molecules, 21.10.3390/molecules21091265 ↗
19. A thermodynamic analysis of the binding interaction between polysorbate 20 and 80 with human serum albumins and immunoglobulins: A contribution to understand colloidal protein stabilisation10.1016/j.bpc.2009.04.004 ↗
20. (2021, September 03). Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, Available online: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Appendix-C.
21. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery10.1016/j.addr.2008.09.002 ↗
22. Bioenhanced sublingual tablet of drug with limited permeability using novel surfactant binder and microencapsulated polysorbate: In vitro/in vivo evaluation10.1016/j.ejpb.2015.06.006 ↗
23. Formulation, development, and optimization of a novel octyldodecanol-based nanoemulsion for transdermal delivery of ceramide IIIB10.2147/IJN.S139975 ↗
24. The effects of excipients on protein aggregation during agitation: An interfacial shear rheology study10.1002/jps.23622 ↗
25. Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions10.1021/js980175v ↗
26. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats10.1007/BF02976689 ↗
27. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro10.1002/jps.10176 ↗
28. Modulation of intestinal p-glycoprotein function by Cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes10.1002/jps.20017 ↗
29. Effect of polyoxyl 35 castor oil and polysorbate 80 on the intestinal absorption of digoxin in vitro
30. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways10.1002/jps.21190 ↗
31. Biosafety materials: An emerging new research direction of materials science from the COVID-19 outbreak10.1039/D0QM00255K ↗
32. (2021, September 03). Safety Assessment of Polysorbates as Used in Cosmetics. Available online: https://www.cir-safety.org/sites/default/files/polysorbates.pdf.
33. A comparative study of the hydroxyl and saponification values of polysorbate 60 in international food additive specifications10.4236/ajac.2014.53024 ↗
34. Food additive emulsifiers: A review of their role in foods, legislation and classifications, presence in food supply, dietary exposure, and safety assessment10.1093/nutrit/nuaa038 ↗
35. Scientific opinion on the re-evaluation of polyoxyethylene sorbitan monolaurate (E 432), polyoxyethylene sorbitan monooleate (E 433), polyoxyethylene sorbitan monopalmitate (E 434), polyoxyethylene sorbitan monostearate (E 435) and polyoxyethylene sorbitan tristearate (E 436) as food additives
36. Kriegel, C., Festag, M., Kishore, R.S.K., Roethlisberger, D., and Schmitt, G. (2020). Pediatric safety of polysorbates in drug formulations. Children, 7.10.3390/children7010001 ↗
37. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice
38. Final report on the safety assessment of polysorbates 20, 21, 40, 60, 61, 65, 80, 81, and 8510.3109/10915818409021272 ↗
39. Preparations of carbon-l4-labeled polyoxyethylene (20) sorbitan monolaurate and their metabolic fate in rats10.1111/j.1365-2621.1966.tb00489.x ↗
40. Nutritional studies on rats on diets containing high levels of partial ester emulsifiers. III. Clinical and metabolic observations10.1093/jn/61.1.149 ↗
41. Comparison of cytotoxicity in vitro and irritation in vivo for aqueous and oily solutions of surfactants10.3109/03639045.2014.938656 ↗
42. Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release10.1002/(SICI)1099-1263(199905/06)19:3<163::AID-JAT561>3.0.CO;2-H ↗
43. Polysorbate 80 hypersensitivity reactions: A renewed call to action10.1016/S1548-5315(11)70418-1 ↗
44. Hepatotoxicity after continuous amiodarone infusion in a postoperative cardiac infant
45. Gameiro, M., Silva, R., Rocha-Pereira, C., Carmo, H., Carvalho, F., Bastos, M.L., and Remião, F. (2017). Cellular models and in vitro assays for the screening of modulators of P-gp, MRP1 and BCRP. Molecules, 22.10.3390/molecules22040600 ↗
46. P-glycoprotein and membrane roles in multidrug resistance10.4155/fmc.15.36 ↗
47. Reversal of multidrug resistance phenotype by surfactants: Relationship to membrane lipid fluidity10.1006/abbi.1995.1298 ↗
48. Modulation of intestinal transport and absorption of topotecan, a BCRP substrate, by various pharmaceutical excipients and their inhibitory mechanisms of BCRP transporter10.1016/j.xphs.2018.10.043 ↗
49. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines10.1016/S0168-3659(03)00163-9 ↗
50. Montmorillonite-surfactant hybrid particles for modulating intestinal P-glycoprotein-mediated transport10.1016/j.ijpharm.2019.118696 ↗
51. Therapeutic efficacy of nanoparticles and routes of administration10.1186/s40824-019-0166-x ↗
52. The potential of lipid emulsion for ocular delivery of lipophilic drugs10.1016/j.ejpb.2004.03.033 ↗
53. Phase behavior of the microemulsions and the stability of the chloramphenicol in the microemulsion-based ocular drug delivery system10.1016/j.ijpharm.2005.06.006 ↗
54. Industrial perspective in ocular drug delivery10.1016/j.addr.2006.07.022 ↗
55. Non-ionic surfactant based organogels incorporating niosomes
56. The potential of chitosan in ocular drug delivery10.1211/0022357022476 ↗
57. Occular drug delivery system—Emerging trends
58. Surface-active agents and the eye
59. Ocular tolerance of preservatives and alternatives10.1016/S0939-6411(01)00246-6 ↗
60. Ophthalmic vehicles containing polymer-solubilized tropicamide: “in vitro/in vivo” evaluation10.1081/DDC-120001491 ↗
61. In vivo characterisation of a novel water-soluble cyclosporine a prodrug for the treatment of dry eye disease10.1016/j.ejpb.2011.11.017 ↗
62. Optimizing flurbiprofen-loaded NLC by central composite factorial design for ocular delivery10.1088/0957-4484/22/4/045101 ↗
63. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension10.1159/000065608 ↗
64. Indomethacin-loaded solid lipid nanoparticles for ocular delivery: Development, characterization, and in vitro evaluation10.1089/jop.2012.0069 ↗
65. Development and evaluation of dexamethasone nanomicelles with potential for treating posterior uveitis after topical application10.1089/jop.2014.0152 ↗
66. Studies on the stability of the chloramphenicol in the microemulsion free of alcohols10.1016/j.ejpb.2005.09.006 ↗
67. Hydrocortisone delivery to healthy and inflamed eyes using a micellar polysorbate 80 solution or albumin nanoparticles10.1016/0378-5173(94)90243-7 ↗
68. Recent advances in non-ionic surfactant vesicles (niosomes): Self-assembly, fabrication, characterization, drug delivery applications and limitations10.3109/10717544.2013.838077 ↗
69. Niosomes as nanoparticular drug carriers: Fundamentals and recent applications10.1155/2016/7372306 ↗
70. Bartelds, R., Nematollahi, M.H., Pols, T., Stuart, M.C.A., Pardakhty, A., Asadikaram, G., and Poolman, B. (2018). Niosomes, an alternative for liposomal delivery. PLoS ONE, 13.10.1371/journal.pone.0194179 ↗
71. Mazet, R., Yaméogo, J.B.G., Wouessidjewe, D., Choisnard, L., and Gèze, A. (2020). Recent advances in the design of topical ophthalmic delivery systems in the treatment of ocular surface inflammation and their biopharmaceutical evaluation. Pharmaceutics, 12.10.3390/pharmaceutics12060570 ↗
72. Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 6010.1016/j.jconrel.2017.03.386 ↗
73. Polysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administration10.1016/j.ijpharm.2018.07.035 ↗
74. Biomedical applications of microemulsion through dermal and transdermal route10.1016/j.biopha.2018.10.021 ↗
75. Effect of liposomes on percutaneous penetration of lipophilic materials10.1016/0378-5173(92)90050-C ↗
76. Development and characterization of eucalyptol microemulsions for topic delivery of curcumin10.1248/cpb.59.172 ↗
77. Terpene microemulsions for transdermal curcumin delivery: Effects of terpenes and cosurfactants10.1016/j.colsurfb.2010.08.018 ↗
78. Microemulsions containing medium-chain glycerides as transdermal delivery systems for hydrophilic and hydrophobic drugs10.1208/s12249-009-9251-0 ↗
79. Microemulsion formulations for the transdermal delivery of testosterone10.1016/j.ejps.2010.03.008 ↗
80. Investigation of microemulsion system for transdermal delivery of meloxicam10.1016/j.ijpharm.2006.06.021 ↗
81. Niosomes vs microemulsions: New carriers for topical delivery of Capsaicin10.1016/j.colsurfb.2011.05.041 ↗
82. Water in oil microemulsions containing NaCl for transdermal delivery of fluorouracil
83. The novel formulation design of O/W microemulsion of ketoprofen for improving transdermal absorption
84. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues10.1073/pnas.84.21.7735 ↗
85. Membrane transporters in drug development10.1038/nrd3028 ↗
86. Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense10.1016/j.taap.2004.10.012 ↗
87. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo10.1016/j.ijpharm.2004.03.001 ↗
88. Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats10.1016/j.ijpharm.2016.09.011 ↗
89. Polysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-Dawley rats10.1016/j.ijpharm.2018.04.006 ↗
90. Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption10.1016/j.ijpharm.2019.05.033 ↗
91. Development and pharmacokinetic evaluation of erythromycin lipidic formulations for oral administration in rainbow trout (Oncorhynchus mykiss)10.1016/j.ejpb.2011.03.007 ↗
92. Improved intestinal delivery of salmon calcitonin by water-in-oil microemulsions10.1016/j.ijpharm.2011.06.029 ↗
93. Enhanced water dispersibility of curcumin encapsulated in alginate-polysorbate 80 nano particles and bioavailability in healthy human volunteers10.2174/2211738507666190122121242 ↗
94. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice10.1016/j.ejpb.2008.02.023 ↗
95. Self-emulsifying drug delivery system of rosuvastatin calcium
96. Preformulation and in vitro physicochemical characterization of fenofibrate-loaded emulsion10.1007/s40005-015-0223-y ↗
97. Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate10.1208/aapsj0903041 ↗
98. Effect of polysorbate 80 on the intranasal absorption and brain distribution of tetramethylpyrazine phosphate in rats10.1007/s13346-018-0580-y ↗
99. Intranasal delivery of formulations containing virucidal lipids for treatment of respiratory syncytial virus (RSV) infection in rats10.1016/S1773-2247(13)50065-7 ↗
100. Nanoparticle-mediated delivery of neurotoxin-II to the brain with intranasal administration: An effective strategy to improve antinociceptive activity of neurotoxin10.3109/03639045.2011.592533 ↗